EAU 2013 - Programme Book - YouMed

Sunday, 17 March - EAU Programme
Abstract Session
12.15 - 13.45 Nocturia, OAB, metabolic syndrome - towards a new management
Silver Hall - Level N2
Poster Session 34
Chairs: P. Abrams, Bristol (GB)
B.A. Dybowski, Warsaw (PL)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion. Extended presentations (*) are 4 minutes in length, followed
by 2 minutes for discussion.
* 401 The incidence of antimuscarinic-associated side effects in overactive bladder (OAB) patients treated with
mirabegron: Results of a pooled analysis of 3 randomised phase 3 trials
V. Nitti, C.R. Chapple, G. Amarenco, P. Radziszewski, J. Angulo, M.B. Blauwet, E. Siddiqui, N. Martin (New
York, Northbrook, United States of America; Sheffield, Chertsey, United Kingdom; Paris, France; Warsaw,
Poland; Madrid, Spain)
402 Tolenix (THVD-201), a novel combination of muscarinic agonist (tolterodine) and muscarinic agonist
(pilocarpine), is efficacious in OAB with less dry mouth compared to tolterodine alone
R. Dmochowski, K. Duchin, T. Tremblay, M. Paborji, R. Flugel (Nashville, Mountain View, United States of
America)
403 The assessment of a novel Transdermal Amplitude Modulated Signal (TAMS) for the treatment of overactive
bladder syndrome
M. Slovak, A.T. Barker, C.R. Chapple (Sheffield, United Kingdom)
404 Clinical efficacy and safety evaluation of imidafenacin as add-on treatment for residual overactive bladder
symptoms in BPH patients with nocturia; addition study sub-analysis
M. Gotoh, M. Takeda, O. Nishizawa, M. Yoshida, S. Takahashi, N. Masumori (Nagoya, Yamanashi,
Matsumoto, Ohbu, Tokyo, Sapporo, Japan)
* 405 ‘My sleep pattern is a series of naps’. Subjective patient-reported data on what is most bothersome about
nocturia
T. Holm-Larsen, C. Albei, F. Andersson, J.P. Nørgaard (Farum, Copenhagen, Denmark; Parsippany, United
States of America)
406 Nocturia has a strong impact on productivity - a comparison with different chronic diseases
F. Andersson, A. Blemings, T. Holm-Larsen, J.P. Nörgaard (Copenhagen, Farum, Denmark)
407 Predictors of improvement amongst men with a predominant complaint of nocturia
O.O. Cäkir, B.T. Helfand, K.T. McVary (Chicago, Evanston, United States of America)
408 An assessment of actual medical management of BPH in a cross-sectional study performed with
administrative health services databases
L. Cindolo, C. Fanizza, M. Romero, L. Pirozzi, F. Berardinelli, C. De Nunzio, P. Sountoulides, L. Schips (Vasto-
Chieti, Rome, Italy; Veria, Greece)
409 Impact of concurrent statins and 5α-reductase inhibitors use on serum PSA and prostate volume in BPH
patients
K.J. Joo, Y.S. Cho, C.H. Kwon, H.J. Park (Seoul, South Korea)
EAU Milan 2013
183
Sunday